Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

Satoshi Kitazawa, PhD, Yukiko Ishii, PhD, Keiko Makita-Suzuki, Koichi Saito, PhD, Kensuke Takayanagi, Hiromi Sugihara, Shun Matsuda, PhD, Takayuki Yamakawa, PhD, Yasuhiro Tsutsui, Tadashi Tanaka, Tomohisa Hatta, PhD, Tohru Natsume, PhD, Toru Kondo, PhD, Yuichi Ishikawa, MD PhD, Shinji Hagiwara, PhD, Hitoshi Kiyoi, MD PhD

Blood (2019) 134 (Supplement_1): 2663.

https://doi.org/10.1182/blood-2019-121869

Published: 2019

Journal Articles

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

Nadia Jaekel, MD, Karolin Hubert, Mathias Hänel, MD, Georg Maschmeyer, MD, Regina Herbst, MD, Susann Schulze, MD, Song-Yau Wang, MD, Christoph Kahl, MD, Maxi Wass, MD, Herbert G. Sayer, MD PhD, Oana Brosteanu, PhD, Dietger Niederwieser, MD, Haifa Kathrin Al-Ali

Blood (2018) 132 (Supplement 1): 83.

https://doi.org/10.1182/blood-2018-99-115790

Published: 2018

Journal Articles

SAMHD1 Is Variably Expressed in Mantle Cell Lymphoma and Correlated to SOX11 but Not to Survival

Agata Magdalena Wasik, PhD MSc, Elin Marin, MD, Magali Merrien, MSc, Joana de Matos Rodrigues, PhDstudent, Martin Lord, PhD, Ioanna Xagoraris, MD, Birger Christensson, MD PhD, George Rassidakis, MD PhD, Mats Jerkeman, Sara Ek, PhD, Birgitta Sander, MD PhD

Blood (2018) 132 (Supplement 1): 4136.

https://doi.org/10.1182/blood-2018-99-118087

Published: 2018

Journal Articles

Risk Score Generated from Ara-C Metabolic Pathway Predicts Leukemic Cell Intracellular Ara-CTP Levels in AML-97 Pediatric Patients

Abdelrahman Elsayed, BSc, MSc, Kristine R Crews, PharmD, Xueyuan Cao, PhD, Jeffrey E Rubnitz, MD PhD, Stanley Pounds, PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 2666.

https://doi.org/10.1182/blood.V130.Suppl_1.2666.2666

Published: 2017

Journal Articles

Association between Gene Expression Levels of Candidate Cytarabine Pathway and Treatment Outcome Using Publically Available Data from Target Project

Abdelrahman Elsayed, BSc, MSc, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 1400.

https://doi.org/10.1182/blood.V130.Suppl_1.1400.1400

Published: 2017

Journal Articles

Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level

Catja Freiburghaus, PhD, Venera Kuci Emruli, PhD, Angelica Johansson, Roger Olsson, PhD, Fredrik Ek, PhD, Christian H Geisler, Mats Jerkeman, Sara Ek, PhD

Blood (2016) 128 (22): 1769.

https://doi.org/10.1182/blood.V128.22.1769.1769

Published: 2016

Journal Articles

Fludarabine, cytarabine and Idarubicin (FLAI-5) with or without Gemtuzumab Ozogamicin Is an Effective and Well Tolerated Regimen for Younger AML Patients: Real Life Data from a Single Center Register

Fabio Guolo, MD, Paola Minetto, MD, Giordana Pastori, MD, Livia Giannoni, MD, Nicoletta Colombo, PhD, Raffaella Grasso, PhD, Francesco Trovato, MD, Marcella Bado, MD, Filippo Ballerini, MD, Marino Clavio, MD, Barbara Rebesco, MD, Maurizio Miglino, PhD, Andrea Bacigalupo, MD, Marco Gobbi, MD, Roberto Lemoli, MD

Blood (2014) 124 (21): 2266.

https://doi.org/10.1182/blood.V124.21.2266.2266

Published: 2014

Journal Articles

Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium

Christian M. Zwaan, MD PhD, Michael Dworzak, MD PhD, Thomas Klingebiel, MD, Claudia Rössig, MD, Guy Leverger, MD, Jan Stary, Evelina S. de Bont, MDPhD, Satianand Ramnarain, MSc, Yves Bertrand, MD, Benoit Brethon, MD, Brigitte Strahm, MD, Gertjan J. Kaspers, MD PhD, Dirk Reinhardt, MD PhD

Blood (2014) 124 (21): 989.

https://doi.org/10.1182/blood.V124.21.989.989

Published: 2014

Journal Articles

Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium

Christian M. Zwaan, Michael Dworzak, Thomas Klingebiel, MD, Claudia Rossig, MD, Guy Leverger, MD, Jan Stary, Evelina S. De Bont, MD, PhD, Satianand Ramnarain, MSc, Yves Bertrand, MD, Essam A Ghazaly, MD, Dirk Reinhardt

Blood (2013) 122 (21): 2693.

https://doi.org/10.1182/blood.V122.21.2693.2693

Published: 2013

Journal Articles

Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights On Potential Preferential Formation of Ara-CTP Directly From Elacytarabine As Well As From Ara-C

Corinne Seng Yue, Varsha V. Gandhi, Ph.D., Susan O'Brien, M.D., Farhad Ravandi, MD, Tove Flem Jacobsen, Hubert Dirven, PhD, Steinar Hagen, PhD, Petter-Arnt Hals, PhD, Murray Ducharme, PhD

Blood (2012) 120 (21): 3547.

https://doi.org/10.1182/blood.V120.21.3547.3547

Published: 2012

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., John Perentesis, MD, James A. Whitlock, MD, Jeffrey W. Taub, MD, Terzah M. Horton, MD, PhD, Alan S. Gamis, MD, MPH, Bassem I. Razzouk, MD

Blood (2012) 120 (21): 3604.

https://doi.org/10.1182/blood.V120.21.3604.3604

Published: 2012

Journal Articles

Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML,

Ajay Abraham, M.Sc, Savitha Varatharajan, M.Sc, Ashok kumar Jayavelu, M.Sc, Shaji R Velayudhan, M.Sc, Ph.D, Rayaz Ahmed, MD, Aby Abraham, MD, Biju George, MD, Mammen Chandy, MD, Alok Srivastava, MD, Vikram Mathews, MD, Poonkuzhali Balasubramanian, M.Sc., Ph.D

Blood (2011) 118 (21): 3481.

https://doi.org/10.1182/blood.V118.21.3481.3481

Published: 2011

Journal Articles

Pathway Based Pharmacogenomics of Cytarabine In Pediatric Acute Myeloid Leukemia

Jatinder Lamba, PhD, Amit Mitra, Kristine Crews, Pounds Stanley, PhD, Xueyuan Cao, PhD, Varsha Gandhi, PhD, William Plunkett, PhD, Jeffrey Rubnitz, MD, PhD, Raul Ribeiro

Blood (2010) 116 (21): 294.

https://doi.org/10.1182/blood.V116.21.294.294

Published: 2010

Journal Articles

Clinical Evaluation of An in Vitro Assay for Rapid Assessment of Cytosine Arabinoside Response in Patients with Acute Leukaemia and Chronic Lymphocytic Leukaemia.

Elizabeth Anderson, Vyv Salisbury, PhD, M. Ann Smith, PhD, Mark Ruddock, PhD, Ashley Martin, PhD, John Lamont, PhD, Habib M Alloush, PhD, K. Stephen Suh, PhD, Graham Smith, MD

Blood (2009) 114 (22): 1608.

https://doi.org/10.1182/blood.V114.22.1608.1608

Published: 2009

Journal Articles

AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.

Todd Cooper, DO, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, John Perentesis, James A. Whitlock, MD, Elizabeth Raetz, MD, William L. Carroll, MD, Alan S. Gamis, MD, B. I. Razzouk

Blood (2009) 114 (22): 3076.

https://doi.org/10.1182/blood.V114.22.3076.3076

Published: 2009

Journal Articles

5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia.

Jatinder K. Lamba, Amit Mitra, Kristine Crews, Stanley Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Jeffrey Rubnitz, Raul C Ribeiro

Blood (2009) 114 (22): 593.

https://doi.org/10.1182/blood.V114.22.593.593

Published: 2009

Journal Articles

Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.

Jatinder K. Lamba, Kristine Crews, Stanley Pounds, Xueyuan Cao, Varsha Gandhi, William Plunkett, Sharyn D. Baker, Ching-Hon Pui, Dario Campana, James R. Downing, MD, Jeffrey Rubnitz, Raul C Ribeiro

Blood (2009) 114 (22): 114.

https://doi.org/10.1182/blood.V114.22.114.114

Published: 2009

Journal Articles

Phase 2 Study of FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report From the Japan Adult Leukemia Study Group (JALSG).

Shuichi Miyawaki, MD, PhD, Naoko Hatsumi, MD, Takahiro Yamauchi, MD, Kousuke Tsuboi, MD, Atsushi Fujieda, MD, Akihiro Takeshita, MD, Norio Komatsu, MD, Noriko Usui, MD, Yukihiro Arai, MD, Fumihiro Ishida, MD, PhD, Takeshi Morii, MD, Yasuhiko Kano, MD, Michinori Ogura, MD, PhD, Noriko Doki, MD, Kazunori Ohnishi, MD, Tomoki Naoe, MD, Ryuzo Ohno, MD

Blood (2009) 114 (22): 1058.

https://doi.org/10.1182/blood.V114.22.1058.1058

Published: 2009

Journal Articles

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Gautam Borthakur, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Dan Jones, MD, PhD, Varsha Gandhi, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Farhad Ravandi, MD, Joyce Bass, RN, Mark Brandt, Hagop Kantarjian, MD

Blood (2009) 114 (22): 2056.

https://doi.org/10.1182/blood.V114.22.2056.2056

Published: 2009

Journal Articles

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

Blood (2008) 112 (11): 2966.

https://doi.org/10.1182/blood.V112.11.2966.2966

Published: 2008

NARROW

Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells

Outcome at Two Years after a Response-Adapted Approach with Azacitidine and Intensive Chemotherapy in Patients > 60 Years with Newly Diagnosed AML Treated within the DRKS00004519 Trial of the East German Study Group (OSHO)

SAMHD1 Is Variably Expressed in Mantle Cell Lymphoma and Correlated to SOX11 but Not to Survival

Risk Score Generated from Ara-C Metabolic Pathway Predicts Leukemic Cell Intracellular Ara-CTP Levels in AML-97 Pediatric Patients

Association between Gene Expression Levels of Candidate Cytarabine Pathway and Treatment Outcome Using Publically Available Data from Target Project

Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level

Fludarabine, cytarabine and Idarubicin (FLAI-5) with or without Gemtuzumab Ozogamicin Is an Effective and Well Tolerated Regimen for Younger AML Patients: Real Life Data from a Single Center Register

Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium

Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium

Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights On Potential Preferential Formation of Ara-CTP Directly From Elacytarabine As Well As From Ara-C

AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia

Expression of Ara-C Metabolizing Enzymes Mediates in Vitro Sensitivity to Ara-C in Primary AML Cells From Patients with Denovo AML,

Pathway Based Pharmacogenomics of Cytarabine In Pediatric Acute Myeloid Leukemia

Clinical Evaluation of An in Vitro Assay for Rapid Assessment of Cytosine Arabinoside Response in Patients with Acute Leukaemia and Chronic Lymphocytic Leukaemia.

AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.

5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia.

Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia.

Phase 2 Study of FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report From the Japan Adult Leukemia Study Group (JALSG).

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only